Nektar Therapeutics (NKTR) has been developing rezpegaldesleukin, or rezpeg, for atopic dermatitis, such as in its REZOLVE-AD trial, and for alopecia areata in the REZOLVE-AA trial. In December 2025, I rated NKTR a buy, noting that while initial data
CryptoAlerta — análise de criptomoedas e mercado em tempo real